Multisystemic sarcoidosis associated with a second therapy for chronic hepatitis C.
Hepatitis C virus (HCV) infection is a very common chronic infectious disease. Combined antiviral therapy including pegylated interferon and ribavirine is presently the standard treatment, with sustained viral response rate over 50%. Interferon induces the development of several autoimmune diseases. Some cases of induced sarcoidosis have been described (affecting mostly lungs, skin and eyes), both with standard and pegylated interferon. We report the case of an African woman, heterozygote for sickle cell anaemia mutation and for glucose-6-phosphate-deshydrogenase (G6PD) deficiency, who developed a multisystemic sarcoidosis (skin, lungs, liver, salivary and lachrymal glands, peripheral nerves), confirmed by biopsies, in the course of a second treatment with pegylated interferon and ribavirine for hepatitis C. The antiviral treatment was discontinued and all symptoms regressed spontaneously within some weeks.
Froidure
A
A
Department of General Internal Medicine, St Luc University Hospital, Brussels, Belgium. a_froidure@hotmail.com
Horsmans
Y
Y
Lefebvre
C
C
D000998:Antiviral Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011994:Recombinant Proteins; D012507:Sarcoidosis / Q000139:chemically induced*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins